**Figures:**



**Figure 01: X-ray diffractograms of REPGLINIDE.**



**Figure 02: X-ray diffractograms of P1 controlled release pellets formulation of REPAGLINIDE.**



**Figure 03: Drug release profile of Repaglinide from coated pellet formulations P1 to P9 (n=3), no. of experiments.**

**Figure 04: Scanning electron microphotographs of pellets: (a), (b) & (c) surface morphology of uncoated pellets.**

**Figure 05: Scanning electron microphotographs of coated pellets: (a), (b) smooth surface and (c) size range of coated pellets.**



 **Figure 06: Scanning electron morphology study of coated pellets with specific time interval exposure to dissolution study. (1 to 9)**



**Figure 07: Scanning electron morphology study of coated pellets with decrease in diameter size after specific time interval exposure to dissolution study.**

**Figure captions:**

**Figure 01: X-ray diffractograms of REPGLINIDE.**

**Figure 02: X-ray diffractograms of P1 controlled release pellets formulation of REPAGLINIDE.**

**Figure 03: Drug release profile of Repaglinide from coated pellet formulations P1 to P9 (n=3), no. of experiments.**

**Figure 04: Scanning electron microphotographs of pellets: (a), (b) & (c) surface morphology of uncoated pellets.**

**Figure 05: Scanning electron microphotographs of coated pellets: (a), (b) smooth surface and (c) size range of coated pellets.**

**Figure 06: Scanning electron morphology study of coated pellets with specific time interval exposure to dissolution study. (1 to 9).**

**Figure 07: Scanning electron morphology study of coated pellets with decrease in diameter size after specific time interval exposure to dissolution study.**